The management of asthma and chronic obstructive pulmonary disease: current status and future perspectives

References

• Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy65(2), 152–167 (2010).
   PubMed Web of Science ®Google Scholar
• Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, International Study of Asthma and Allergies in Childhood Phase Three Study Group. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood.(ISAAC). Thorax64(6), 476–483 (2009).
   PubMed Web of Science ®Google Scholar
• Chinn S, Jarvis D, Burney P et al. Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health Survey. Thorax59(8), 646–651 (2004).
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Bucca C, Neri M et al. Asthma severity and medical resource utilisation. Eur. Respir. J.23(5), 723–729 (2004).
   PubMed Web of Science ®Google Scholar
• Soriano JB, Rodríguez-Roisin R. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc. Am. Thorac. Soc.8(4), 363–367 (2011).
   PubMedGoogle Scholar
• Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int. J. Chron. Obstruct. Pulmon. Dis.4, 137–148 (2009).
   PubMedGoogle Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet364, 709–721 (2004).
   PubMed Web of Science ®Google Scholar
• Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.5(4), 549–555 (2008).
   PubMedGoogle Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br. Med. J.1, 1645–1648 (1977).
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med.182(5), 598–604 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Gómez FP, Benet M et al.; on behalf of the PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax66(5), 430–437 (2011).
   PubMed Web of Science ®Google Scholar
• Casanova C, de Torres JP, Aguirre-Jaíme A et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am. J. Respir. Crit. Care Med.184(9), 1015–1021 (2011).
   PubMed Web of Science ®Google Scholar
• Rivera-Fernandez R, Navarrete-Navarro P, Fernandez-Mondejar E, Rodriguez-Elvira M, Guerrero-Lopez F, Vazquez-Mata G. Project for the Epidemiological Analysis of Critical Care Patients (PAEEC) Group. Six-year mortality and quality of life in critically ill patients with chronic obstructive pulmonary disease. Crit. Care Med.34(9), 2317–2324 (2006).
   PubMedGoogle Scholar
• Ambrosino N, Bruletti G, Scala V, Porta R, Vitacca M. Cognitive and perceived health status in patients recovering from an acute exacerbation of COPD. A controlled study. Intensive Care Med.28(2), 170–177 (2002).
   PubMedGoogle Scholar
• Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J.29(6), 1224–1238 (2007).
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax57(10), 847–852 (2002).
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.157(5), 1418–1422 (1998).
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur. Respir. J.31(1), 204–212 (2008).
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronicobstructive pulmonary disease. Am. J. Respir. Crit. Care Med.179(5), 369–374 (2009).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J.16(5), 802–807 (2000).
   PubMed Web of Science ®Google Scholar
• Demoly P, Paggiaro P, Plaza V et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur. Respir. Rev.18(112), 105–112 (2009).
   PubMedGoogle Scholar
• Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs68(12), 1741–1770 (2008).
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Nicolini G, Papi A. Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. Expert Rev. Respir. Med.2(2), 161–166 (2008).
   PubMedGoogle Scholar
• Contoli M, Bousquet J, Fabbri LM et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy65(2), 141–151 (2010).
   PubMed Web of Science ®Google Scholar
• Humbert M, Andersson TL, Buhl R. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy63(12), 1567–1580 (2008).
   PubMed Web of Science ®Google Scholar
• Haahtela T, Tuomisto LE, Pietinalho A et al. A 10 year asthma programme in Finland: major change for the better. Thorax61(8), 663–670 (2006).
   PubMed Web of Science ®Google Scholar
• Camargo CA Jr, Gurner DM, Smithline HA et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J. Allergy Clin. Immunol.125(2), 374–380 (2010).
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med.155(2), 179–191 (2011).
   PubMed Web of Science ®Google Scholar
• Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs70(17), 2269–2280 (2010).
   PubMed Web of Science ®Google Scholar
• Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.11(5), CD002309 (2011).
   Google Scholar
• Clini EM, Ambrosino N. Non pharmacological treatment and relief of symptoms. Eur. Respir. J.332(1), 218–228 (2008).
   Google Scholar
• Nici L, Donner C, Wouters E et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med.173(12), 1390–1413 (2006).
   PubMed Web of Science ®Google Scholar
• Clini E, Ambrosino N. Rehabilitation in COPD patients: evergreen in pneumology and beyond. Eur. Respir. J.38(3), 514–515 (2011).
   PubMedGoogle Scholar
• Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.10, CD005305 (2011).
   PubMed Web of Science ®Google Scholar
• Criner GJ. Alternatives to lung transplantation: lung volume reduction for COPD. Clin. Chest Med.32(2), 379–397 (2011).
   PubMedGoogle Scholar
• Sciurba FC, Ernst A, Herth FJ et al. A randomized study of endobronchial valves for advanced emphysema. N. Engl. J. Med.363(13), 1233–1244 (2010).
   PubMed Web of Science ®Google Scholar
• Slebos DJ, Klooster K, Ernst A, Herth FJ, Kerstjens HA. Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema. Chest138(4, Suppl.), A829 (2011).
   Google Scholar
• Refaely Y, Dransfield M, Kramer MR et al. Biologic lung volume reduction therapy for advanced homogeneous emphysema. Eur. Respir. J.36(1), 20–27 (2010).
   PubMed Web of Science ®Google Scholar
• Lahzami S, Bridevaux PO, Soccal PM et al. Survival impact of lung transplantation for COPD. Eur. Respir. J.36(1), 74–80 (2010).
   PubMed Web of Science ®Google Scholar
• Clini E, Sturani C, Rossi A et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur. Respir. J.20(3), 529–538 (2002).
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med.365(8), 689–698 (2011).
   PubMed Web of Science ®Google Scholar
• Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.19(1), CD004403 (2011).
   Google Scholar
• Ambrosino N, Vagheggini G. Noninvasive positive pressure ventilation in the acute care setting: where are we? Eur. Respir. J.31(4), 874–886 (2008).
   PubMed Web of Science ®Google Scholar
• Alía I, de la Cal MA, Esteban A et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch. Intern. Med.171(21), 1939–1946 (2011).
   PubMed Web of Science ®Google Scholar
• Walters JA, Wang W, Morley C, Soltani A, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.10, CD006897 (2011).
   Google Scholar
• Guilbert TW, Morgan WJ, Zeiger RS et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med.354(19), 1985–1997 (2006).
   PubMed Web of Science ®Google Scholar
• Strunk RC, Sternberg AL, Szefler SJ, Zeiger RS, Bender B, Tonascia J. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J. Pediatr.154(5), 682–687 (2009).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. Am. J. Respir. Crit. Care Med.179(1), 19–24 (2009).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J. Allergy Clin. Immunol.126(5), 926–938 (2010).
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet360(9347), 1715–1721 (2002).
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Mauger DT, Sorkness CA et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med.362(11), 975–985 (2010).
   PubMed Web of Science ®Google Scholar
• Vorrink SN, Kort HS, Troosters T, Lammers JW. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir. Res.12, 33 (2011).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.359(15), 1543–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet374(9696), 1171–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med.178(4), 332–338 (2008).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.356(8), 775–789 (2007).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest.118(11), 3546–3556 (2008).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol. Sci.31(7), 335–343 (2010).
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest139(1), 28–35 (2011).
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med.179(7), 549–558 (2009).
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med.360(10), 973–984 (2009).
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med.360(10), 985–993 (2009).
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med.183(8), 1007–1014 (2011).
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med.365(12), 1088–1098 (2011).
   PubMed Web of Science ®Google Scholar
• Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur. Respir. Rev.19(115), 46–54 (2010).
   PubMedGoogle Scholar
• Cox G. Bronchial thermoplasty for severe asthma. Curr. Opin. Pulm. Med.17(1), 34–38 (2011).
   PubMedGoogle Scholar
• Barnes PJ. Emerging pharmacotherapies for COPD. Chest134(6), 1278–1286 (2008).
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Mölken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost–Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet365(9470), 1552–1560 (2005).
   PubMed Web of Science ®Google Scholar
• Roth MD, Connett JE, D’Armiento JM et al. Feasibility of retinoids for the treatment of emphysema study. Chest130(5), 1334–1345 (2006).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Wedzicha JA. Controversies in treatment of chronic obstructive pulmonary disease. Lancet378(9795), 1038–1047 (2011).
   PubMed Web of Science ®Google Scholar
• McLean S, Nurmatov U, Liu JL, Pagliari C, Car J, Sheikh A. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.6(7), CD007718 (2011).
   Google Scholar